HK1120212A1 - Dispersible bosertan tablet - Google Patents

Dispersible bosertan tablet

Info

Publication number
HK1120212A1
HK1120212A1 HK08112061.1A HK08112061A HK1120212A1 HK 1120212 A1 HK1120212 A1 HK 1120212A1 HK 08112061 A HK08112061 A HK 08112061A HK 1120212 A1 HK1120212 A1 HK 1120212A1
Authority
HK
Hong Kong
Prior art keywords
dispersible
bosertan
tablet
pyrimidin
benzenesulfonamide
Prior art date
Application number
HK08112061.1A
Other languages
English (en)
Inventor
Lovelace Holman
Timm Trenktrog
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37431647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1120212(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of HK1120212A1 publication Critical patent/HK1120212A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK08112061.1A 2005-05-17 2008-11-04 Dispersible bosertan tablet HK1120212A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2005005367 2005-05-17
PCT/IB2006/051519 WO2006123285A2 (en) 2005-05-17 2006-05-15 Dispersible bosertan tablet

Publications (1)

Publication Number Publication Date
HK1120212A1 true HK1120212A1 (en) 2009-03-27

Family

ID=37431647

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08112061.1A HK1120212A1 (en) 2005-05-17 2008-11-04 Dispersible bosertan tablet

Country Status (24)

Country Link
US (3) US7959945B2 (pt)
EP (1) EP1883397B1 (pt)
JP (1) JP4219399B2 (pt)
KR (2) KR20080014002A (pt)
CN (1) CN101175484B (pt)
AT (1) ATE451914T1 (pt)
AU (1) AU2006248593B2 (pt)
BR (1) BRPI0610187B8 (pt)
CA (1) CA2607098C (pt)
CY (1) CY1110610T1 (pt)
DE (1) DE602006011150D1 (pt)
DK (1) DK1883397T3 (pt)
ES (1) ES2336943T3 (pt)
HK (1) HK1120212A1 (pt)
IL (1) IL187383A (pt)
MX (1) MX2007014454A (pt)
NO (1) NO339781B1 (pt)
NZ (1) NZ564167A (pt)
PL (1) PL1883397T3 (pt)
PT (1) PT1883397E (pt)
RU (2) RU2404774C2 (pt)
SI (1) SI1883397T1 (pt)
WO (1) WO2006123285A2 (pt)
ZA (1) ZA200710903B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4219399B2 (ja) 2005-05-17 2009-02-04 アクテリオン ファーマシューティカルズ リミテッド 分散性錠剤
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
CA2712860C (en) 2008-02-08 2014-11-18 Abhay Gaitonde Process for preparing bosentan
CN102272108A (zh) 2008-11-03 2011-12-07 基因里克斯(英国)有限公司 用于分析波生坦及相关物质的hplc方法以及这些物质作为参比标准和标记的用途
JP5850576B2 (ja) * 2010-07-06 2016-02-03 富士化学工業株式会社 ボセンタン固体分散体
CN102114005B (zh) * 2010-12-06 2012-12-12 武汉武药科技有限公司 一种波生坦胶囊及其制备方法
WO2012139736A1 (en) 2011-04-11 2012-10-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Pharmaceutical composition comprising bosentan
ES2841809T3 (es) 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
JP2015503555A (ja) 2012-05-11 2015-02-02 ハナル・バイオファーマ・カンパニー・リミテッド ボセンタン制御放出性経口製剤
KR101451327B1 (ko) * 2013-01-08 2014-11-03 안국약품 주식회사 보센탄의 제어방출성 다층 정제 및 그 제조방법
RU2559424C1 (ru) * 2014-06-18 2015-08-10 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения Российской Федерации (ФГБУ "РКНПК" Минздрава России) Способ подбора лекарственной терапии больным с идиопатической легочной гипертензией
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
CN104840965B (zh) * 2015-05-05 2018-05-08 重庆华邦制药有限公司 波生坦的制剂及其稳定剂
KR20160141045A (ko) 2015-05-27 2016-12-08 한올바이오파마주식회사 보센탄을 함유한 약학적 조성물
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
CN108703956A (zh) * 2018-08-21 2018-10-26 天津双硕医药科技有限公司 一种含有波生坦的固体药物组合物
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)
WO2023107066A2 (en) * 2021-12-07 2023-06-15 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Bosentan pharmaceutical compositions
WO2023128902A1 (en) * 2021-12-30 2023-07-06 Pharmactive Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions comprising bosentan and relevant excipients
CN114533738A (zh) * 2022-02-19 2022-05-27 苏州海景医药科技有限公司 一种波生坦固体药物组合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
US6635648B2 (en) * 2000-08-18 2003-10-21 Queen's University At Kingston Combination therapy using sympathetic nervous system antagonists and endothelin antagonists
EP1509524B1 (en) * 2002-05-31 2008-03-26 Schering Corporation Xanthine phosphodiesterase v inhibitor polymorphs
KR100604034B1 (ko) 2003-10-08 2006-07-24 주식회사유한양행 암로디핀 유리염기를 함유한 구강 속붕해정 및 그의 조성물
JP4219399B2 (ja) * 2005-05-17 2009-02-04 アクテリオン ファーマシューティカルズ リミテッド 分散性錠剤

Also Published As

Publication number Publication date
SI1883397T1 (sl) 2010-04-30
BRPI0610187A2 (pt) 2010-06-01
NO339781B1 (no) 2017-01-30
US20130023547A1 (en) 2013-01-24
NZ564167A (en) 2009-12-24
WO2006123285A3 (en) 2007-07-05
CN101175484A (zh) 2008-05-07
AU2006248593A1 (en) 2006-11-23
DK1883397T3 (da) 2010-04-06
RU2007146395A (ru) 2009-06-27
US8309126B2 (en) 2012-11-13
CA2607098A1 (en) 2006-11-23
JP4219399B2 (ja) 2009-02-04
PL1883397T3 (pl) 2010-05-31
MX2007014454A (es) 2008-02-07
NO20076325L (no) 2008-02-04
CY1110610T1 (el) 2015-04-29
US20110245281A1 (en) 2011-10-06
WO2006123285A2 (en) 2006-11-23
DE602006011150D1 (de) 2010-01-28
US7959945B2 (en) 2011-06-14
IL187383A0 (en) 2008-02-09
PT1883397E (pt) 2010-02-23
KR20100093105A (ko) 2010-08-24
RU2404774C2 (ru) 2010-11-27
US20080193528A1 (en) 2008-08-14
RU2010129460A (ru) 2012-01-27
KR20080014002A (ko) 2008-02-13
ES2336943T3 (es) 2010-04-19
BRPI0610187B8 (pt) 2021-05-25
CA2607098C (en) 2012-04-10
ATE451914T1 (de) 2010-01-15
EP1883397B1 (en) 2009-12-16
IL187383A (en) 2011-09-27
BRPI0610187B1 (pt) 2020-03-03
AU2006248593B2 (en) 2011-03-17
JP2008540512A (ja) 2008-11-20
EP1883397A2 (en) 2008-02-06
ZA200710903B (en) 2008-12-31
CN101175484B (zh) 2012-02-01

Similar Documents

Publication Publication Date Title
ZA200710903B (en) Dispersible bosertan tablet
UY29500A1 (es) Proceso quimico
WO2007027238A3 (en) Jak kinase inhibitors and their uses
NO2014029I2 (no) Sofosbuvir. (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropyrimidin-1(2H)-yl)-4-fluor-3-hydroksy-4-metyltetrahydrofuran-2-yl)metoksy)-(fenoksy)fosforylamino)propanoat
AP2004003182A0 (en) Microbicidal pyrimidine or triazine for preventingsexual HIV transmission.
ATE500232T1 (de) Kristalline form von 2-chlor-5-ä3,6-dihydro-3- methyl-2,6-dioxo-4-(trifluormethyl)-1-(2h)- pyrimidinylü-4-fluor-n-äämethyl-(1- methylethyl)aminoüsulfonylübenzamid
RS20050810A (en) 5,7-diaminopyrazolo(4,3-d)pyrimidines useful in the treatment of hypertension
MX2010004576A (es) Derivados de pirimidina novedosos.
DE602004032321D1 (de) Die hiv-replikation inhibierende indan-substituierte pyrimidine
EP1869056A4 (en) NOVEL SUBSTITUTED 7-AMINO-Ý1,3¨THIAZOLOÝ4,5-d¨PYRIMIDINE DERIVATIVES
EP1948193A4 (en) AMINOPYRIMIDINES SUITABLE AS KINASEINHIBITORS
ATE420646T1 (de) Aminopyrimidine als kinase-modulatoren
NZ705225A (en) Process for preparing antiviral compounds
TN2010000070A1 (en) Fused bicyclic pyrimidines
ATE542802T1 (de) Hiv-inhibierende 5-substituierte pyrimidine
UA83314C2 (ru) 2-(пиридин-2-ил)пиримидиновые соединения и их применение для борьбы с вредными грибами
CL2011003022A1 (es) Compuestos derivados de 2,4 diaminopirimidina, inhibidores de quinasa ptk2; composicion farmaceutica que comprende a uno de los compuestos, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva, tal como cancer.
DK2203444T3 (da) Faste former af (S)-ethyl-2-amino-3-(4-(2-amino-6-((R)-1-(4-chlor-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluorethoxy)pyrimidin-4-yl)phenyl)propanoat
ZA201002214B (en) 3-methyl-2-((2s)-2-(4-(3-methyl-l,2,4-0xadiazol-5-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3h)-one as tau protein kinase inhibitor
HK1149003A1 (en) 4-aminopyrimidine derivatives as histamine h4 receptor antagonists
TR201903012T4 (tr) Bosentan monohidratın ve bunun ara ürünlerinin hazırlanması için proses.
MX2011005611A (es) Sintesis y formas de sales novedosas de (r)-5-((e)-2-(pirrolidin-3 -il-vinil)pirimidina.
IL182419A0 (en) Use of 4- (4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms
ZA200804599B (en) Aminopyrimidines useful as kinase inhibitors
TW200738720A (en) 7-Amino-6-heteroaryl-1,2,4-triazolo[1,5-a]pyrimidine compounds and their use for controlling harmful fungi